Poolbeg Pharma plc – Interim Results for the six months to 30 June 2026
Strong operational progress as TOPICAL trial builds momentum
29 September 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2026.
